Table 10. Meta-analysis of effectiveness outcomes with exclusion of studies, which contribute to heterogeneity (random-effect model) Survival, percentage (95% confidence interval), I2 Indication N studies On N studies At N studies 30-day (n pts) support (n pts) discharge (n pts) 88% 74% VAD support in pre-cardiotomy 4 (40) (70-99%), - - 5 (60) (56-87%), cardiogenic shock indication I2=50.9% I2=56% 54% 71% VAD support in post-LVAD placement - - 3 (48) (40-68%), 2 (36) (50-88%), ventricular failure indication I2= 0% I2= 39.7% Pts patients; VAD, ventricular assist device. –
Table 10. Meta-analysis of effectiveness outcomes with exclusion of studies, which contribute to heterogeneity (random-effect model) Indication Survival, percentage (95% confidence interval), I2 N studies (n pts) On support N studies (n pts) At discharge N studies (n pts) 30-day VAD support in pre-cardiotomy cardiogenic shock indication 4 (40) 88% (70-99%), I2=50.9% - - 5 (60) 74% (56-87%), I2=56% VAD support in post-LVAD placement ventricular failure indication - - 3 (48) 54% (40-68%), I2= 0% 2 (36) 71% (50-88%), I2= 39.7% Pts – patients; VAD, ventricular assist device.